专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007027748A2 C/CLP ANTAGONISTS AND METHODS OF USE THEREOF 审中-公开
标题翻译： C / CLP ANTAGONISTS及其使用方法
公开(公告)号：WO2007027748A2
公开(公告)日：2007-03-08
申请号：PCT/US2006/033825
申请日：2006-08-30
申请人： MEDIMMUNE, INC. , YALE UNIVERSITY , REED, Jennifer, Lynne , WHITE, Wendy , COYLE, Anthony , ELIAS, Jack , KOZHICH, Alexander
发明人： REED, Jennifer, Lynne , WHITE, Wendy , COYLE, Anthony , ELIAS, Jack , KOZHICH, Alexander
IPC分类号： A61K39/395 , C07K16/44
CPC分类号： C07K16/40 , A61K48/00 , A61K2039/505 , C07K2317/21 , C07K2317/52 , C07K2317/622 , C07K2317/76 , C07K2319/00 , C12N9/2442 , C12N15/86 , C12N2710/10343 , C12Y302/01014
摘要： The invention relates to the novel discovery that antagonizing a C/CLP can be useful for the treatment of diseases associated with the upregulation of one or more C/CLP such as Th2-driven and/or IL- 13 mediated inflammatory diseases. Accordingly the present invention provides C/CLP antagonists and also provides compositions and methods for the prevention, management, treatment or amelioration of an inflammatory condition associated with the upregulation of a C/CLP or one or more symptoms thereof and/or the inhibition of IL- 13 mediated inflammation.
摘要翻译：本发明涉及拮抗C / CLP的新发现可用于治疗与上调一种或多种C / CLP（例如Th2驱动和/或IL-13介导的炎性疾病）相关的疾病。因此，本发明提供了C / CLP拮抗剂，并且还提供了用于预防，治疗，改善与C / CLP或其一种或多种症状的上调相关的炎性病症和/或抑制IL的组合物和方法 - 13介导的炎症。

2. 发明申请

WO2008150431A1 IL- 18 AND PROTEIN KINASE R INHIBITION FOR THE TREATMENT OF COPD 审中-公开
标题翻译：用于治疗COPD的IL-18和蛋白激酶R抑制
公开(公告)号：WO2008150431A1
公开(公告)日：2008-12-11
申请号：PCT/US2008/006821
申请日：2008-05-29
申请人： YALE UNIVERSITY , ELIAS, Jack , LEE, Chun, Guen , KANG, Min-Jong
发明人： ELIAS, Jack , LEE, Chun, Guen , KANG, Min-Jong
IPC分类号： A61K45/00
CPC分类号： A61K31/00 , G01N2333/5421 , G01N2333/555 , G01N2333/912
摘要： The present invention encompasses compositions and methods directed to preventing, inhibiting, or treating inflammation, alveolar remodeling, or cell death in lung which results from elevation of IL- 18, IFN-γ, or PKR where the methods of the present invention comprise administering an IL- 18 inhibitor, an IL-18Rα inhibitor, and IFNγ inhibitor, a PKR inhibitor, and any combination thereof to an individual experiencing inflammation, alveolar remodeling, or cell death in lung. The present invention further encompasses a method of alleviating exacerbations of COPD frequently caused by viral infection by administering inflammation, alveolar remodeling, or cell death in lung to a patient with COPD at risk of developing a viral infection or who has acquired a viral infection.
摘要翻译：本发明包括用于预防，抑制或治疗由IL-18，IFN-γ或PKR升高引起的肺中的炎症，肺泡重塑或细胞死亡的组合物和方法，其中本发明的方法包括给予 IL-18抑制剂，IL-18Ra抑制剂和IFNγ 抑制剂，PKR抑制剂及其任何组合与经历肺部炎症，肺泡重塑或细胞死亡的个体。本发明还包括通过在患有发展为病毒感染或已经获得病毒感染的风险的COPD患者中施用炎症，肺泡重塑或肺部细胞死亡而缓解由病毒感染引起的COPD加重的方法。

3. 发明申请

WO2008048560A3 TOLL-LIKE RECEPTOR AGONIST REGULATION OF VEGF-INDUCED TISSUE RESPONSES 审中-公开
公开(公告)号：WO2008048560A3
公开(公告)日：2008-04-24
申请号：PCT/US2007/022009
申请日：2007-10-16
申请人： YALE UNIVERSITY , ELIAS, Jack
发明人： ELIAS, Jack
IPC分类号： C07K2/00 , A61K31/7115
摘要： The present invention encompasses compositions and compounds as well as methods of their use for the regulation of a VEGF-induced tissue response. A VEGF- induced tissue response may include angiogenesis, inflammation, increased vascular permeability, increased vascular leak, hemorrhage, or mucus metaplasia. As such, the present invention encompasses methods of treating diseases where a VEGF-induced tissue response is part of the disease's clinical presentation. Specifically, the present invention provides compounds and compositions as well as methods for treating acute lung injury (ALI), acute respiratory distress syndrome (ARDS), asthma, chronic obstructive pulmonary disease (COPD), obstructive sleep apnea (OSA), idiopathic pulmonary fibrosis (IPF), tuberculosis, pulmonary hypertension, pleural effusion, and lung cancer.

4. 发明申请

WO2008024300A1 SEMAPHORIN 7A PLAYS A CRITICAL ROLE IN TGF-β1-INDUCED PULMONARY FIBROSIS AND ALVEOLAR DESTRUCTION 审中-公开
标题翻译： SEMAPHORIN 7A播放TGF-β1诱导的肺动脉纤维化和血液破坏中的关键作用
公开(公告)号：WO2008024300A1
公开(公告)日：2008-02-28
申请号：PCT/US2007/018356
申请日：2007-08-20
申请人： YALE UNIVERSITY , ELIAS, Jack , LEE, Chun, Geun
发明人： ELIAS, Jack , LEE, Chun, Geun
IPC分类号： A01N37/18 , A61K38/00 , A61K48/00 , C07K1/00 , C07K14/00 , C07K17/00 , A61K39/395 , C07H21/04
CPC分类号： A61K31/00 , A61K38/177 , C07K16/18
摘要： The present invention provides methods of treating a subject diagnosed with, or at risk for developing, pathogenic fibrosis, particularly pulmonary fibrosis. The method of the invention comprises administering to the subject a compound or composition which inhibits semaphorin (SEMA) 7A, SEMA 7A receptors, or downstream effectors. A SEMA 7A inhibitor comprises an antibody, a soluble SEMA 7A receptor, an siRNA, a ribozyme, an antisense, an aptamer, a peptidomimetic, a small molecule, a soluble receptor, or any combinations thereof.
摘要翻译：本发明提供了治疗被诊断患有或具有发展为致病性纤维化，特别是肺纤维化的风险的受试者的方法。本发明的方法包括向受试者施用抑制信号素（SEMA）7A，SEMA 7A受体或下游效应物的化合物或组合物。 SEMA 7A抑制剂包括抗体，可溶性SEMA 7A受体，siRNA，核酶，反义，适体，肽模拟物，小分子，可溶性受体或其任何组合。

5. 发明申请

WO2004089395A3 USE OF AN INHIBITOR OF CATHEPSIN-S OR -B TO TREAT OR PREVENT CHRONIC OBSTRUCTIVE PULMONARY DISEASE 审中-公开
公开(公告)号：WO2004089395A3
公开(公告)日：2004-10-21
申请号：PCT/US2004/009959
申请日：2004-04-01
申请人： AVENTIS PHARMACEUTICALS INC. , YALE UNIVERSITY , ZHENG, Tao , ELIAS, Jack , UNDERWOOD, Stephen
发明人： ZHENG, Tao , ELIAS, Jack , UNDERWOOD, Stephen
IPC分类号： A61K38/48
摘要： This invention is directed to the use of an inhibitor of cathepsin-S or -B, or composition thereof, to treat or prevent chronic obstruction pulmonary disease, or physiological condition associated therewith. Such a therapy would occur using at least one of such inhibitors alone or in combination with the other, or further in combination with an anti-inflammatory agent.

6. 发明公开

EP1928496A2 C/CLP ANTAGONISTS AND METHODS OF USE THEREOF 审中-公开
标题翻译： C / CLP拮抗剂和使用方法
公开(公告)号：EP1928496A2
公开(公告)日：2008-06-11
申请号：EP06802602.0
申请日：2006-08-30
申请人： MEDIMMUNE, INC. , Yale University
发明人： REED, Jennifer, Lynne , WHITE, Wendy , COYLE, Anthony , ELIAS, Jack , KOZHICH, Alexander
IPC分类号： A61K39/395 , C07K16/44
CPC分类号： C07K16/40 , A61K48/00 , A61K2039/505 , C07K2317/21 , C07K2317/52 , C07K2317/622 , C07K2317/76 , C07K2319/00 , C12N9/2442 , C12N15/86 , C12N2710/10343 , C12Y302/01014
摘要： The invention relates to the novel discovery that antagonizing a C/CLP can be useful for the treatment of diseases associated with the upregulation of one or more C/CLP such as Th2-driven and/or IL- 13 mediated inflammatory diseases. Accordingly the present invention provides C/CLP antagonists and also provides compositions and methods for the prevention, management, treatment or amelioration of an inflammatory condition associated with the upregulation of a C/CLP or one or more symptoms thereof and/or the inhibition of IL- 13 mediated inflammation.

7. 发明申请

WO2010036628A2 REMOTELY CONFIGURABLE ANALOG/DIGITAL INPUT CIRCUIT AND RELATED APPARATUS AND METHOD 审中-公开
标题翻译：可远程配置的模拟/数字输入电路及相关装置和方法
公开(公告)号：WO2010036628A2
公开(公告)日：2010-04-01
申请号：PCT/US2009/057767
申请日：2009-09-22
申请人： HONEYWELL INTERNATIONAL INC. , ELIAS, Jack , PUNIS, Giancarlo
发明人： ELIAS, Jack , PUNIS, Giancarlo
IPC分类号： G08C17/02 , H04W84/18
CPC分类号： G01D21/00 , G05B19/0423 , G05B19/054 , G05B2219/1157 , Y10T307/76 , Y10T307/944
摘要： An apparatus (200, 600, 900) includes first and second input terminals (208a-208b, 610a-610b, 624a-624b) configured to be coupled to one of multiple types of input sources (210-214). The apparatus also includes a diode (216, 612, 626) and a resistor (218, 614, 628) coupled in series between the first and second input terminals. The apparatus further includes a plurality of switches (220-224, 618-622, 630-634) each coupled to at least one of the diode and the resistor. The switches are configured to be opened and closed to reconfigure the apparatus depending on the type of input source. The switches could include a first switch (220, 618, 630) coupled to the first input terminal, a current source (226, 648), and a first side of the diode. The switches could also include a second switch (222, 620, 632) coupled to the current source, a second side of the diode, and a first side of the resistor. In addition, the switches could include a third switch (224, 622, 634) coupled to the second input terminal and a second side of the resistor.
摘要翻译：一种装置（200,600,900）包括被配置为耦合到多种类型的输入源（210）中的一个的第一和第二输入端子（208a-208b，610a-610b，624a-624b） -214）。该装置还包括串联耦合在第一和第二输入端子之间的二极管（216,612,626）和电阻器（218,614,628）。该装置还包括多个开关（220-224,618-622,630-634），每个开关耦合到二极管和电阻器中的至少一个。开关配置为打开和关闭，以根据输入源的类型重新配置设备。开关可以包括耦合到第一输入端子的第一开关（220,618,630），电流源（226,648）以及二极管的第一侧。开关还可以包括耦合到电流源，二极管的第二侧和电阻器的第一侧的第二开关（222,620,632）。另外，开关可以包括耦合到第二输入端子和电阻器的第二侧的第三开关（224,622,634）。

8. 发明公开

EP2164517A1 IL- 18 AND PROTEIN KINASE R INHIBITION FOR THE TREATMENT OF COPD 审中-公开
标题翻译： IL-18和蛋白激酶R-抑制COPD的治疗
公开(公告)号：EP2164517A1
公开(公告)日：2010-03-24
申请号：EP08767942.9
申请日：2008-05-29
申请人： Yale University
发明人： ELIAS, Jack , LEE, Chun, Guen , KANG, Min-Jong
IPC分类号： A61K45/00
CPC分类号： A61K31/00 , G01N2333/5421 , G01N2333/555 , G01N2333/912
摘要： The present invention encompasses compositions and methods directed to preventing, inhibiting, or treating inflammation, alveolar remodeling, or cell death in lung which results from elevation of IL- 18, IFN-γ, or PKR where the methods of the present invention comprise administering an IL- 18 inhibitor, an IL-18Rα inhibitor, and IFNγ inhibitor, a PKR inhibitor, and any combination thereof to an individual experiencing inflammation, alveolar remodeling, or cell death in lung. The present invention further encompasses a method of alleviating exacerbations of COPD frequently caused by viral infection by administering inflammation, alveolar remodeling, or cell death in lung to a patient with COPD at risk of developing a viral infection or who has acquired a viral infection.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式